Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“Mayvenn brought on FLG at a time when our finance department was in really bad shape. Within sixty days of coming on-board, our books were completely cleaned up, compliance and processes completely re-designed, and the right, full-time hires were made to ensure continuity. FLG was able to pair us with a partner, Patty Fukami, who had the appropriate expertise, but who was also a good cultural fit. This firm is highly professional and has integrity. I’m very pleased with them and recommend them to any company looking to either turn around or take their finance department to the next level.”
